DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.
DEM BioPharma has raised $70.0M in total funding. The most recent round was Series A. The last funding was announced in June 2022.
DEM BioPharma's investors include Insight Venture Management, LLC., Longwood Fund, Pfizer Venture Investments, Alexandria Venture Investments, Alta Partners.
DEM BioPharma is headquartered in Cambridge, United States.
DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.
DEM BioPharma is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"DEM BioPharma — Funding & Investors." VCBacked, June 23, 2022, https://www.vcbacked.co/company/dem-biopharma. Accessed November 13, 2026.
VCBacked. (2022). DEM BioPharma — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/dem-biopharma
{{cite web |title=DEM BioPharma — Funding & Investors |url=https://www.vcbacked.co/company/dem-biopharma |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at DEM BioPharma? Request a listing update